Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice